Boston Scientific (NYSE:BSX) Updates Q2 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.710-0.730 for the period, compared to the consensus earnings per share estimate of 0.710. The company issued revenue guidance of -, compared to the consensus revenue estimate of $4.8 billion. Boston Scientific also updated its FY 2025 guidance to 2.870-2.940 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BSX shares. UBS Group raised their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Morgan Stanley raised their price target on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Needham & Company LLC upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $113.00 price target for the company in a research report on Wednesday, April 16th. Raymond James lifted their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $110.22.

Boston Scientific Stock Performance

Shares of BSX opened at $94.96 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a 50-day simple moving average of $99.00 and a 200-day simple moving average of $94.55. The stock has a market capitalization of $140.45 billion, a PE ratio of 75.97, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific has a 1 year low of $67.80 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the sale, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock valued at $14,407,381 over the last quarter. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,376 shares of the medical equipment provider’s stock after buying an additional 226 shares during the period. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent filing with the Securities and Exchange Commission. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.